NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $90,000 | -14.3% | 5,264 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $105,000 | -57.5% | 5,264 | -50.7% | 0.00% | -50.0% |
| Q2 2020 | $247,000 | +263.2% | 10,686 | +182.4% | 0.00% | – |
| Q1 2020 | $68,000 | -55.0% | 3,784 | -46.1% | 0.00% | -100.0% |
| Q4 2019 | $151,000 | -27.8% | 7,019 | -39.0% | 0.00% | 0.0% |
| Q3 2019 | $209,000 | -97.0% | 11,500 | -94.2% | 0.00% | -96.9% |
| Q2 2019 | $7,062,000 | -0.4% | 198,491 | -6.0% | 0.03% | 0.0% |
| Q1 2019 | $7,092,000 | +203.2% | 211,064 | +196.6% | 0.03% | +190.9% |
| Q4 2018 | $2,339,000 | -68.7% | 71,155 | -42.0% | 0.01% | -60.7% |
| Q3 2018 | $7,482,000 | +44.6% | 122,729 | +15.8% | 0.03% | +33.3% |
| Q2 2018 | $5,176,000 | -86.5% | 106,005 | -70.7% | 0.02% | -86.1% |
| Q1 2018 | $38,395,000 | +1.1% | 361,330 | -43.2% | 0.15% | +5.6% |
| Q4 2017 | $37,996,000 | +89.9% | 636,245 | -23.7% | 0.14% | +81.0% |
| Q3 2017 | $20,010,000 | +19.0% | 833,747 | -3.0% | 0.08% | +16.2% |
| Q2 2017 | $16,812,000 | -38.2% | 859,945 | -25.8% | 0.07% | -39.8% |
| Q1 2017 | $27,186,000 | +104.2% | 1,158,340 | +6.7% | 0.11% | +85.2% |
| Q4 2016 | $13,314,000 | -19.3% | 1,085,113 | +12.9% | 0.06% | -22.8% |
| Q3 2016 | $16,506,000 | -13.2% | 960,783 | -28.1% | 0.08% | -16.0% |
| Q2 2016 | $19,025,000 | +4.0% | 1,336,970 | +0.5% | 0.09% | +3.3% |
| Q1 2016 | $18,297,000 | -19.9% | 1,330,718 | -1.8% | 0.09% | -19.5% |
| Q4 2015 | $22,843,000 | +60.5% | 1,355,677 | +4.4% | 0.11% | +50.7% |
| Q3 2015 | $14,236,000 | -16.0% | 1,298,915 | -4.1% | 0.08% | -11.8% |
| Q2 2015 | $16,941,000 | +40.1% | 1,354,235 | +23.2% | 0.08% | +39.3% |
| Q1 2015 | $12,093,000 | -18.7% | 1,099,348 | +14.5% | 0.06% | -19.7% |
| Q4 2014 | $14,878,000 | +42.0% | 959,901 | +10.6% | 0.08% | +49.0% |
| Q3 2014 | $10,475,000 | -3.5% | 867,827 | +2.5% | 0.05% | -3.8% |
| Q2 2014 | $10,855,000 | +0.2% | 846,728 | -5.3% | 0.05% | +3.9% |
| Q1 2014 | $10,837,000 | +9.8% | 894,155 | +2.8% | 0.05% | +10.9% |
| Q4 2013 | $9,870,000 | +9.7% | 869,620 | +1.0% | 0.05% | +4.5% |
| Q3 2013 | $8,998,000 | -14.0% | 861,089 | -4.9% | 0.04% | -17.0% |
| Q2 2013 | $10,458,000 | – | 905,456 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |